Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

Abstract Background Large cell neuroendocrine tumor (LCNEC) of the lung is a rare and aggressive tumor similar to small cell lung cancer (SCLC). Thus, it is often treated similarly to SCLC in the front-line setting with a platinum doublet. However, treatment for patients beyond the first line remain...

Full description

Bibliographic Details
Main Authors: Victoria E. Wang, Anatoly Urisman, Lee Albacker, Siraj Ali, Vincent Miller, Rahul Aggarwal, David Jablons
Format: Article
Language:English
Published: BMJ Publishing Group 2017-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Large cell neuroendocrine tumor
Pembrolizumab
PD-L1
Tumor mutation burden
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-017-0281-y

Internet

http://link.springer.com/article/10.1186/s40425-017-0281-y

Similar Items